Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 148

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 148
---
 complied with by us;                               |

| ● | the absence of any material                                                           
 misstatement or omission in the registration statement that includes this prospectus; |

80

| ● | the final prospectus, in final                                                                                                        
 form, and all reports, schedules, registrations, forms, statements, information and other documents required to have been filed by us 
 with the SEC pursuant to the reporting requirements of the Exchange Act having been so filed;                                         |

| ● | the Common Stock not having                                                                                                            
 been suspended by the SEC, Nasdaq or any Eligible Market, or FINRA and there not having been imposed any suspension of, or restriction 
 on, accepting additional deposits of Common Stock by The Depository Trust Company;                                                     |

| ● | no condition, occurrence, state                                                                                                      
 of facts or event constituting a Material Adverse Effect (as defined in the Keystone Purchase Agreements) shall have occurred and be 
 continuing;                                                                                                                          |

| ● | customary compliance with laws         
 and bankruptcy-related conditions; and |

| ● | the receipt by Keystone of                                          
 customary legal opinions, as required under the Purchase Agreement. |

Termination of the Keystone Purchase Agreements Unless earlier terminated as provided in the Keystone Purchase Agreements, the Keystone Purchase Agreements will terminate automatically on the earliest to occur of:

| ● | the 36-month anniversary of                                  
 the effective date of the applicable Registration Statement; |

| ● | the date on which Keystone                                                                 
 has purchased the Keystone Commitment Amount pursuant to the Keystone Purchase Agreements; |

| ● | the date on which our Common                                                 
 Stock fails to be listed or quoted on the Nasdaq or any Eligible Market; and |

| ● | the 30th trading day following                                                                                                                
 the date on which, pursuant to or within the meaning of any bankruptcy law, we commence a voluntary case or any person commences a proceeding 
 against us, a custodian is appointed for us or for all or substantially all of our property, or we make a general assignment for the          
 benefit of our creditors.                                                                                                                     |

We have the right to terminate the Keystone Purchase Agreements at any time after the Keystone Commencement Date, at no cost or penalty, upon one trading days’ prior written notice to Keystone, provided that we shall have issued all Keystone Commitment Shares to Keystone prior to such termination. We and Keystone may also terminate the Keystone Purchase Agreements at any time by mutual written consent. Keystone also has the right to terminate the Keystone Purchase Agreements upon 10 trading days